Copernicus Capital Management is an investment fund managing more than $6.34 million ran by John Rende. There are currently 11 companies in Mr. Rende’s portfolio. The largest investments include Vertex Pharmaceuticals and Fate Therapeutics Inc, together worth $2.68 million.
As of 9th August 2021, Copernicus Capital Management’s top holding is 9,000 shares of Vertex Pharmaceuticals currently worth over $1.82 million and making up 28.6% of the portfolio value.
Relative to the number of outstanding shares of Vertex Pharmaceuticals, Copernicus Capital Management owns more than approximately 0.1% of the company.
In addition, the fund holds 10,000 shares of Fate Therapeutics Inc worth $868 thousand, whose value fell 14.5% in the past six months.
The third-largest holding is Atara Biotherapeutics Inc worth $778 thousand and the next is Zentalis Pharmaceuticals, Llc worth $532 thousand, with 10,000 shares owned.
Currently, Copernicus Capital Management's portfolio is worth at least $6.34 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Copernicus Capital Management office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, John Rende serves as the Managing Partner at Copernicus Capital Management.
In the most recent 13F filing, Copernicus Capital Management revealed that it had opened a new position in
Atara Biotherapeutics Inc and bought 50,000 shares worth $778 thousand.
On the other hand, there are companies that Copernicus Capital Management is getting rid of from its portfolio.
Copernicus Capital Management closed its position in Abbvie Inc on 16th August 2021.
It sold the previously owned 110,000 shares for $10.8 million.
John Rende also disclosed a decreased stake in Vertex Pharmaceuticals by 0.6%.
This leaves the value of the investment at $1.82 million and 9,000 shares.
The two most similar investment funds to Copernicus Capital Management are White Rock Capital Management, L.P. and Covalis (gibraltar) Ltd. They manage $6.52 million and $6.16 million respectively.
Copernicus Capital Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 90.0% of
the total portfolio value.
The fund focuses on investments in the United States as
72.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
9% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $8.47 billion.
These positions were updated on August 16th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Abbvie Inc |
Closed
110,000
|
$10,800,000 | |
| Bristol-Myers Squibb Co. |
Closed
171,493
|
$10,084,000 | |
| Alexion Pharmaceuticals Inc. |
Closed
85,000
|
$9,540,000 | |
| AMGEN Inc. |
Closed
33,000
|
$7,783,000 | |
| Biomarin Pharmaceutical Inc. |
Closed
49,889
|
$6,153,000 | |
| IQVIA Holdings Inc |
Closed
40,000
|
$5,675,000 | |
| MyoKardia, Inc. |
Closed
57,000
|
$5,507,000 | |
| Arena Pharmaceuticals Inc |
Closed
79,672
|
$5,015,000 | |
| Momenta Pharmaceuticals, Inc. |
Closed
88,000
|
$2,928,000 | |
| GW Pharmaceuticals |
Closed
22,000
|
$2,700,000 | |
| Eiger BioPharmaceuticals Inc |
Closed
200,000
|
$1,920,000 | |
| Vertex Pharmaceuticals, Inc. |
59.65%
9,000
|
$1,815,000 | 28.62% |
| Translate Bio Inc |
Closed
90,000
|
$1,613,000 | |
| Cymabay Therapeutics Inc |
Closed
287,000
|
$1,002,000 | |
| Orasure Technologies Inc. |
Closed
78,875
|
$917,000 | |
| Fate Therapeutics Inc |
93.57%
10,000
|
$868,000 | 13.69% |
| Atara Biotherapeutics Inc |
Opened
50,000
|
$778,000 | 12.27% |
| Zentalis Pharmaceuticals, Llc |
Opened
10,000
|
$532,000 | 8.39% |
| TCR2 Therapeutics Inc. |
Opened
30,000
|
$492,000 | 7.76% |
| Horizon Therapeutics Pub L |
94.09%
5,000
|
$468,000 | 7.38% |
| Accolade, Inc. |
Opened
7,000
|
$380,000 | 5.99% |
| Jazz Pharmaceuticals plc |
Opened
2,000
|
$355,000 | 5.60% |
| Gritstone Bio Inc |
Opened
35,000
|
$320,000 | 5.05% |
| The Beauty Health Company |
Opened
10,000
|
$168,000 | 2.65% |
| Arcus Biosciences Inc |
83.92%
20,000
|
$165,000 | 2.60% |
| No transactions found | |||
| Showing first 500 out of 25 holdings | |||